CJC-1295 vs Ipamorelin: Research Profile Comparison
CJC-1295 and Ipamorelin are commonly discussed together in growth-hormone-axis research because they act on different receptors within the same pathway. They are not the same class of compound.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | CJC-1295Growth hormone-releasing hormone (GHRH) analogue | IpamorelinGrowth hormone secretagogue (ghrelin/GHS-R1a receptor agonist) |
| Receptor target | CJC-1295GHRH receptor | IpamorelinGhrelin receptor (GHS-R1a) |
| Selectivity (research literature) | CJC-1295Reported to stimulate GH release with limited effect on other pituitary hormones | IpamorelinReported as one of the more receptor-selective secretagogues studied, with limited reported effect on cortisol or prolactin in preclinical work |
| Regulatory note | CJC-1295On the WADA Prohibited List; no MHRA/UK marketing authorisation — see our legal-status page | IpamorelinOn the WADA Prohibited List; no MHRA/UK marketing authorisation — see our legal-status page |
Takeaway
They act on two different receptors within the same growth-hormone-release pathway rather than being alternative versions of the same mechanism, which is why research literature frequently studies them together rather than as substitutes for one another.
Research-profile comparison for laboratory reference only — not a usage or combination guide. See our legal & compliance hub for the regulatory position on either compound.
Common Questions
What is the difference between a GHRH analogue and a secretagogue?
A GHRH analogue mimics growth hormone-releasing hormone and acts at the GHRH receptor. A secretagogue such as Ipamorelin acts at a different receptor entirely — the ghrelin receptor, GHS-R1a. Both sit in the same growth-hormone-release pathway but enter it at different points.
What does "DAC" mean on a CJC-1295 label?
DAC stands for Drug Affinity Complex, a modification reported to extend the compound's circulating half-life substantially in preclinical models. CJC-1295 is supplied both with and without it, and the two are not interchangeable in a study — check which variant a certificate of analysis refers to. In our catalogue CJC-1295 is supplied only within the CJC-1295 + Ipamorelin preparation, whose certificate states the form.
Are CJC-1295 and Ipamorelin on the WADA Prohibited List?
Yes, both appear on the WADA Prohibited List. The list is revised annually, so verify the current year's edition directly with WADA rather than relying on any supplier page, including this one.
Are either of these licensed medicines in the UK?
Neither holds a UK marketing authorisation. Both are supplied for laboratory research use only. The broader regulatory picture is set out in our UK compliance overview.